Association of methylenetetrahydrofolate reductase (MTHFR) C677T, MTHFR A1298C, and CYP3A4 A290G gene polymorphisms with clinical outcomes of HLA-matched sibling allogeneic hematopoietic cell transplantation in an Egyptian patient/donor cohort.

The impact of non-HLA drug-metabolizing gene polymorphisms on post-transplant outcomes is well recognized. We aimed to evaluate the impact of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T and A1982C and CYP3A4 A290G polymorphisms on the outcomes of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) from fully matched siblings. Using PCR-RFLP and according to DNA availability, MTHFR and CYP3A4-V polymorphisms were evaluated.

The impact of cytokine gene polymorphisms on the outcome of HLA matched sibling hematopoietic stem cell transplantation.

Graft-versus-host disease (GVHD) is the major complication of allogeneic hematopoietic stem cell transplantation (HSCT); cytokines are recognized as important mediators in its pathogenesis. In this study we investigated the role of cytokine gene polymorphisms on HSCT outcome. A total of 106 patient and 98 donors were genotyped by polymerase chain reaction sequence specific primers (PCR-SSP) based assay for tumor necrosis factor-α-308 (TNFα -308), interleukin (IL)-6-174, IL-10-1082, -819, -592, Interferon-γ+874 (IFN-γ+874), and transforming growth factor-β1 (TGF-β1) codon10 and 25 polymorphisms.